APA (7th ed.) Citation

WR, S., Z, K., Z, A., SF, C., BA, K., & LM, S. (2022). Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 36(3), 231. https://doi.org/10.1007/s40259-022-00529-7

Chicago Style (17th ed.) Citation

WR, Strohl, Ku Z, An Z, Carroll SF, Keyt BA, and Strohl LM. "Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 36, no. 3 (2022): 231. https://doi.org/10.1007/s40259-022-00529-7.

MLA (9th ed.) Citation

WR, Strohl, et al. "Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 36, no. 3, 2022, p. 231, https://doi.org/10.1007/s40259-022-00529-7.